Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH276 in Combination With Chemotherapy or Cetuximab in RAS-mutant Metastatic Colorectal Cancer
NCT07915921Phase 2Not yet recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Nov 2026
- Primary completion
- Apr 2028
01
Overview
A Phase 2 trial of GFH276 in colorectal cancer (CRC), sponsored by GenFleet Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
GFH276
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07915921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915921.